Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions
Completed
Torrent Pharmaceuticals Limited
Phase 1
1969-12-31
Objective:
subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride
and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone
hydrochloride and metformin hydrochloride) Tablets 15 mg/850 mg of Takeda Pharmaceuticals
America, Inc. USA. Dosing periods of studies were separated by a washout period of 14 days.
Study Design:
Randomized, Two-Way Crossover, Single-Dose, and Open-Label
Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions
Completed
Torrent Pharmaceuticals Limited
Phase 1
1969-12-31
Objective:
subjects to compare the single dose bioavailability of Torrent's Pioglitazone Hydrochloride
and Metformin Hydrochloride Tablets 15 mg/850 mg and Actoplus Met® (pioglitazone
hydrochloride and metformin hydrochloride) Tablets 15 mg/850 mg of Takeda Pharmaceuticals
America, Inc. USA. Dosing periods of studies were separated by a washout period of 14 days.
Study Design:
Randomized, Two-Way Crossover, Single-Dose, and Open-Label
ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment
Terminated
National Cancer Institute (NCI)
Phase 2
2017-08-14
This randomized phase IIb trial studies how well ACTOplus met XR works in treating in
patients with stage I-IV oral cavity or oropharynx cancer that are undergoing definitive
treatment. Chemoprevention is the use of drugs to keep oral cavity or oropharynx cancer from
forming or coming back. The use of ACTOplus met XR may slow disease progression in patients
with oral cavity or oropharynx cancer.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.